BP1001: Ph II started

Bio-Path began an open-label, U.S. Phase II trial to evaluate 60 mg/m2 IV BP1001 given on day 1 and every 3 days thereafter plus low-dose cytarabine twice daily for 20 consecutive days in each 28-day ...